Ranbaxy Laboratories has reported results for the first quarter ended March 31, 2013.
The company has reported a fall of 91.52% in its net profit at Rs 70.14 crore in Q4FY13 as compared to net profit of Rs 827.23 crore in the same quarter previous year. Total income of the company has decreased by 25.32% to Rs 1433.96 crore as compared to Rs 1920.16 crore in corresponding quarter last year.
On consolidated basis, the company has reported a fall of 89.91% in its net profit at Rs 125.75 crore in Q4FY13 as compared to net profit of Rs 1246.76 crore in the same quarter previous year. Total income of the company has decreased by 33.29% to Rs 2562.96 crore as compared to Rs 3842.02 crore in corresponding quarter last year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1834.40 |
| Dr. Reddys Lab | 1306.80 |
| Cipla | 1362.85 |
| Zydus Lifesciences | 940.10 |
| Lupin | 2459.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: